Clinical trials: Hospital-acquired Pneumonia
Community-Acquired Infections, Pneumonia
Community-acquired Pneumonia in Buskerud County in Norway
The purpose of this study is to determine the etiology of community-acquired pneumonia, to assess risk factors and to investigate potential prognostic biomarkers of serious disease and fatal outcome.
- Trial name
- NCT01563315
- Where
- Norway
- Volunteers
- 270 people
- Sponsor
- Vestre Viken Hospital Trust
Ventilator Associated Pneumonia, Lower Respiratory Infection
Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia
To investigate the pharmacokinetic characteristics of POL7080 co-administered with SoC during 10 to 14 days of treatment in VAP patients due to suspected or documented Pseudomonas aeruginosa infection
- Trial name
- NCT02096328
- Testing
- POL7080
- Where
- 10 sites in Greece, Spain
- Volunteers
- 25 people
- Sponsor
- Polyphor Ltd.
Pneumonia
Improving Oral Care to Reduce Hospital-Acquired Pneumonia (HAP) in the Acute Neurologically Impaired Adult
Hypothesis: The investigators hypothesize that the current oral protocol is sub-optimal and an enhanced protocol will decrease the incidence of hospital acquired pneumonia (HAP)in the acute, non-intubated, care-dependent…
- Trial name
- NCT01498601
- Testing
- Enhanced oral care protocol
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Fraser Health
Nosocomial Infections
Nosocomial Respiratory Virus Infection
Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing…
- Trial name
- NOSOVIRUS (NCT06643039)
- Testing
- Nasopharyngeal swab, Questionnaire
- Where
- 6 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
This is a 2-part study, with Part A being the randomized, controlled portion of the study in patients with ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or bacteremia.
- Conditions
- Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
- Trial name
- ATTACK (NCT03894046)
- Testing
- Sulbactam, Durlobactam, Colistin
- Where
- 90 sites in United States, Belarus and 15 more
- Volunteers
- 207 people
- Sponsor
- Entasis Therapeutics
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Hospital-acquired Pneumonia, Healthcare Associated Infection
Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)
Background: Hospital acquired pneumonia (HAP) is divided in two distinct groups, ventilator-associated pneumonia (VAP) and non-ventilator-associated HAP (nvHAP).
- Conditions
- Hospital-acquired Pneumonia, Healthcare Associated Infection, Infection Prevention
- Trial name
- NCT03361085
- Testing
- nvHAP Prevention Bundle
- Where
- Switzerland
- Volunteers
- 45,000 people
- Sponsor
- University of Zurich
Community Acquired Pneumonia, Hospital Acquired Pneumonia
HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections
HOME FIRST (Home Followed - up with Infection Respiratory Support Team) is an early supported discharge scheme. It will enable patients with lower respiratory tract infection (LRTI) to be provided with high quality safe…
- Conditions
- Community Acquired Pneumonia, Hospital Acquired Pneumonia, Lower Respiratory Tract Infection
- Trial name
- HOMEFIRST (NCT02454114)
- Testing
- HOMEFIRST, Standard Hospital Care
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust